VG Life Sciences Inc. (VGLS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -20.34 Thousand USD | 14.39% |
| 2022 | -23.76 Thousand USD | 97.96% |
| 2021 | -1.16 Million USD | 1.86% |
| 2020 | -1.18 Million USD | -3548.97% |
| 2019 | 34.4 Thousand USD | 0.0% |
| 2018 | 34.4 Thousand USD | 0.0% |
| 2017 | 34.4 Thousand USD | 105.79% |
| 2016 | -594.5 Thousand USD | 0.0% |
| 2014 | -4.14 Million USD | -6.04% |
| 2013 | -3.9 Million USD | -150279.52% |
| 2012 | -2598.51 USD | 0.0% |
| 2006 | -6.37 Million USD | -43.54% |
| 2005 | -4.44 Million USD | 41.88% |
| 2004 | -7.64 Million USD | -80.26% |
| 2003 | -4.24 Million USD | -237.43% |
| 2002 | -1.25 Million USD | -33.27% |
| 2001 | -942.95 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2752.00 USD | 55.9% |
| 2024 Q1 | -6240.00 USD | -10.25% |
| 2023 Q1 | -4070.00 USD | 76.86% |
| 2023 Q2 | -8910.00 USD | -118.92% |
| 2023 Q4 | -5660.00 USD | -232.94% |
| 2023 Q3 | -1700.00 USD | 80.92% |
| 2023 FY | -20.34 Thousand USD | 14.39% |
| 2022 Q3 | -3920.00 USD | 0.0% |
| 2022 Q1 | -2250.00 USD | 35.71% |
| 2022 FY | -23.76 Thousand USD | 97.96% |
| 2022 Q4 | -17.59 Thousand USD | -348.72% |
| 2021 FY | -1.16 Million USD | 1.86% |
| 2021 Q4 | -3500.00 USD | 99.65% |
| 2021 Q3 | -1 Million USD | -520.58% |
| 2021 Q2 | -161.14 Thousand USD | 0.0% |
| 2020 FY | -1.18 Million USD | -3548.97% |
| 2019 FY | 34.4 Thousand USD | 0.0% |
| 2018 FY | 34.4 Thousand USD | 0.0% |
| 2017 FY | 34.4 Thousand USD | 105.79% |
| 2016 FY | -594.5 Thousand USD | 0.0% |
| 2015 Q3 | -644.44 Thousand USD | 12.83% |
| 2015 Q2 | -739.26 Thousand USD | 7.76% |
| 2015 Q1 | -801.48 Thousand USD | -48.02% |
| 2014 Q1 | -1.65 Million USD | 22.62% |
| 2014 Q2 | -1.15 Million USD | 30.27% |
| 2014 Q3 | -798.77 Thousand USD | 30.65% |
| 2014 FY | -4.14 Million USD | -6.04% |
| 2014 Q4 | -541.45 Thousand USD | 32.21% |
| 2013 Q2 | -522.87 Thousand USD | -131744.62% |
| 2013 Q3 | -853.63 Thousand USD | -63.26% |
| 2013 Q4 | -2.13 Million USD | -150.05% |
| 2013 Q1 | -396.59 USD | 0.0% |
| 2013 FY | -3.9 Million USD | -150279.52% |
| 2012 FY | -2598.51 USD | 0.0% |
| 2007 Q1 | -540.62 Thousand USD | 32.54% |
| 2007 Q2 | -870.55 Thousand USD | -61.03% |
| 2007 Q3 | -880.48 Thousand USD | -1.14% |
| 2006 Q2 | -1.74 Million USD | 46.81% |
| 2006 FY | -6.37 Million USD | -43.54% |
| 2006 Q4 | -801.45 Thousand USD | -48.35% |
| 2006 Q3 | -540.25 Thousand USD | 69.1% |
| 2006 Q1 | -3.28 Million USD | -108.15% |
| 2005 Q1 | -1.14 Million USD | 23.17% |
| 2005 Q3 | -640.96 Thousand USD | 42.12% |
| 2005 Q2 | -1.1 Million USD | 3.6% |
| 2005 Q4 | -1.57 Million USD | -146.39% |
| 2005 FY | -4.44 Million USD | 41.88% |
| 2004 FY | -7.64 Million USD | -80.26% |
| 2004 Q1 | -1.66 Million USD | 15.34% |
| 2004 Q2 | -3.51 Million USD | -111.75% |
| 2004 Q3 | -968.63 Thousand USD | 72.47% |
| 2004 Q4 | -1.49 Million USD | -54.36% |
| 2003 FY | -4.24 Million USD | -237.43% |
| 2003 Q4 | -1.96 Million USD | -186.49% |
| 2003 Q1 | -165.66 Thousand USD | 6.78% |
| 2003 Q3 | -685.12 Thousand USD | 51.98% |
| 2003 Q2 | -1.42 Million USD | -761.25% |
| 2002 Q3 | -754.28 Thousand USD | -388.95% |
| 2002 Q2 | -154.26 Thousand USD | 9.47% |
| 2002 Q1 | -170.4 Thousand USD | 76.15% |
| 2002 FY | -1.25 Million USD | -33.27% |
| 2002 Q4 | -177.72 Thousand USD | 76.44% |
| 2001 FY | -942.95 Thousand USD | 0.0% |
| 2001 Q4 | -714.54 Thousand USD | -22714.43% |
| 2001 Q3 | -3132.00 USD | -101.07% |
| 2001 Q1 | -33.65 Thousand USD | 9.11% |
| 2001 Q2 | 292.19 Thousand USD | 968.09% |
| 2000 Q4 | -37.03 Thousand USD | 38.92% |
| 2000 Q3 | -60.62 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | 85.565% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 97.039% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 88.141% |
| CytoDyn Inc. | -18.05 Million USD | 99.887% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.966% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -2714.018% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 98.88% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 99.597% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 32.091% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 88.792% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 99.79% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.963% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.973% |
| Resverlogix Corp. | -12.74 Million USD | 99.84% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 94.779% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 100.209% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 99.172% |
| Mesoblast Limited | -84.14 Million USD | 99.976% |
| GB Sciences, Inc. | -1.42 Million USD | 98.568% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 97.039% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 99.886% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 99.403% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 99.694% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 99.358% |
| ContraFect Corporation | -56.88 Million USD | 99.964% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 99.261% |
| BioStem Technologies, Inc. | -7.77 Million USD | 99.739% |
| LadRx Corporation | -3.82 Million USD | 99.468% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 99.872% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 98.182% |
| CSL Limited | 3.7 Billion USD | 100.001% |
| Biomind Labs Inc. | -1 Million USD | 97.985% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 97.816% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.025% |
| Nascent Biotech, Inc. | -2.22 Million USD | 99.088% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.972% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 100.414% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 100.575% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 98.676% |
| Marizyme, Inc. | -34.08 Million USD | 99.94% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 99.756% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 96.398% |
| Zenith Capital Corp. | -8.94 Million USD | 99.773% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 99.286% |
| Halberd Corporation | -75.05 Thousand USD | 72.898% |
| Genus plc | 6.4 Million USD | 100.318% |
| Pharming Group N.V. | -4.87 Million USD | 99.583% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 98.976% |
| IMV Inc. | -38.67 Million USD | 99.947% |
| Affymax, Inc. | -15.04 Million USD | 99.865% |
| SYBLEU INC | -149.18 Thousand USD | 86.365% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 98.052% |
| Enzolytics Inc. | -2.14 Million USD | 99.053% |
| argenx SE | -425.04 Million USD | 99.995% |
| AVAX Technologies, Inc. | 6.69 Million USD | 100.304% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 98.549% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 98.477% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 99.457% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 19.19% |
| Cell Source, Inc. | -4.32 Million USD | 99.53% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 95.789% |
| Q BioMed Inc. | -3.44 Million USD | 99.41% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 99.52% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 98.381% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 99.226% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 99.553% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.963% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 99.299% |
| Rebus Holdings, Inc. | -664 Thousand USD | 96.937% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 97.933% |
| Skye Bioscience, Inc. | -13.67 Million USD | 99.851% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 98.909% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 98.985% |
| ONE Bio Corp. | 13.68 Million USD | 100.149% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 98.948% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 98.192% |
| Agentix Corp. | -1.37 Million USD | 98.517% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 99.303% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 98.712% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -16.756% |
| Kadimastem Ltd | -3.04 Million USD | 99.331% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 92.229% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 95.104% |
| NovAccess Global Inc. | -2.46 Million USD | 99.175% |
| Itoco Inc. | -919.14 Thousand USD | 97.787% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 90.758% |
| Qrons Inc. | -643.67 Thousand USD | 96.84% |
| Mobile Lads Corp. | -554.55 Thousand USD | 96.332% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.995% |
| International Stem Cell Corporation | -663 Thousand USD | 96.932% |
| Bioxytran, Inc. | -3.82 Million USD | 99.468% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 61.36% |
| Cardax, Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 99.944% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 98.743% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 97.236% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 99.346% |
| Neutra Corp. | -229.48 Thousand USD | 91.137% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 99.884% |
| PureTech Health plc | -146.19 Million USD | 99.986% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 99.905% |
| IXICO plc | -1.43 Million USD | 98.585% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 99.786% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.983% |
| CSL Limited | 3.81 Billion USD | 100.001% |
| Cellectis S.A. | -108.85 Million USD | 99.981% |